We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Targets Sandoz Over Enbrel Biosimilar Efforts
Amgen Targets Sandoz Over Enbrel Biosimilar Efforts
Amgen is taking Novartis’s biosimilar division to court over alleged patent infringement for seeking FDA approval to produce a generic version of its blockbuster drug Enbrel.